Li-Ming Gan

Title: Innovations by Li-Ming Gan

Introduction

Li-Ming Gan is a notable inventor based in Mölndal, Sweden. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target cardiovascular disorders. With a total of 3 patents to his name, Gan's work is recognized for its potential therapeutic applications.

Latest Patents

Gan's latest patents include the development of 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase (MPO). These compounds are designed to inhibit the enzyme MPO, which plays a role in cardiovascular disorders such as heart failure and coronary artery disease. The patents disclose certain compounds of formula (I) and their pharmaceutically acceptable salts, along with compositions containing them and their therapeutic uses.

Career Highlights

Li-Ming Gan is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca focuses on innovative solutions for treating serious health conditions, particularly in the cardiovascular domain. Gan's research has the potential to impact the lives of many patients suffering from heart-related issues.

Collaborations

Some of Gan's notable coworkers include Tord Bertil Inghardt and Petra Johannesson, who contribute to the collaborative efforts in research and development at AstraZeneca.

Conclusion

Li-Ming Gan's innovative work in developing inhibitors for myeloperoxidase showcases his commitment to advancing medical science. His contributions are vital in the ongoing fight against cardiovascular diseases, and his patents reflect a promising future in therapeutic advancements.